Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hoffmeister M et al. - Risk reduction was seen both in estrogen-only therapy and in combination therapy, the latter regardless of the mode of therapy, whether with hormone patches or with oral tablets. In combination with estrogen, progestagens of the norethisterone and levonorgestrel families were associated with strong reduction in CRC risk.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address